Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Actelion decides not to exercise its option to acquire the Marseille-based French biotech Trophos after the failure of that company's lead compound, olesoxime, in a Phase III study in amyotrophic lateral sclerosis
You may also be interested in...
Deal Watch: NASH Space Heats Up With Tobira/Regado Reverse-Merger
Roche buys out French biotech Trophos, with plans to continue developing its failed ALS candidate in spinal muscular atrophy. Meanwhile, the ramifications from last year’s complex Novartis/GSK tie-up continue, as Novartis transfers a Phase III BRAF inhibitor to Array a month after returning a MEK inhibitor to its former partner.
Deals Of The Week: Amgen/Watson, Baxter/Momenta, Takeda/Intellikine
Biosimilars took center stage during the last two weeks of 2011, as Amgen and Watson and then Baxter and Momenta followed up on the collaboration between Biogen Idec and Samsung BioLogics earlier in the month.
First the Activists, Now The Competition: Actelion Faces Continued Challenges
Actelion may have rebuffed activist shareholders Elliott Advisors, but it now faces growing competition in its core PAH franchise.